H.R. 7174 118th Congress
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
- Health
- Sponsor: Rep. Murphy, Gregory F. [R-NC-3]
- Congress.gov ↗
Latest action, Dec 17, 2024: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
17 cosponsors
Sponsored by Rep. Murphy, Gregory F. [R-NC-3] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
2 D · 15 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
4 reports
4 reports
4 reports
4 reports
INCUBATE
NOVEL STRATEGIES (FKA) PRISM GROUP
4 reports
4 reports
4 reports
4 reports
4 reports
4 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
DESIMONE CONSULTING, LLC
4 reports
PHRMA
HORIZON GOVERNMENT AFFAIRS
4 reports
4 reports
All 25 of 27 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS | 4 | $1.4M | Q1 2024 | Q3 2024 | yes | |
| AMGEN INC | 4 | $11.6M | Q1 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $6.7M | Q1 2024 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 4 | $4.8M | Q1 2024 | Q3 2024 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 4 | $214K | Q1 2024 | Q3 2024 | yes | |
| INCUBATE | NOVEL STRATEGIES (FKA) PRISM GROUP | 4 | $120K | Q1 2024 | Q3 2024 | yes |
| INTRA-CELLULAR THERAPIES, INC. | 4 | $210K | Q1 2024 | Q3 2024 | yes | |
| MERCK & CO INC | 4 | $9.2M | Q1 2024 | Q3 2024 | yes | |
| NEUROCRINE BIOSCIENCES, INC | 4 | $3.3M | Q1 2024 | Q3 2024 | yes | |
| NOVARTIS | 4 | $6.0M | Q1 2024 | Q3 2024 | yes | |
| PFIZER INC. | 4 | $8.9M | Q1 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 4 | $31.0M | Q1 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | DESIMONE CONSULTING, LLC | 4 | $120K | Q1 2024 | Q3 2024 | yes |
| PHRMA | HORIZON GOVERNMENT AFFAIRS | 4 | $200K | Q1 2024 | Q3 2024 | yes |
| PTC THERAPEUTICS, INC. | 4 | $760K | Q1 2024 | Q3 2024 | yes | |
| SANOFI US SERVICES INC | 4 | $5.5M | Q1 2024 | Q3 2024 | yes | |
| BAYER CORPORATION (CONSOLIDATED REPORT) | 3 | $6.2M | Q4 2024 | Q3 2024 | yes | |
| HARMONY BIOSCIENCES | 3 | $450K | Q4 2024 | Q3 2024 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 3 | $5.0M | Q4 2024 | Q3 2024 | yes | |
| LUNDBECK LLC | 3 | $420K | Q4 2024 | Q3 2024 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 3 | $1.9M | Q1 2024 | Q2 2024 | yes | |
| PERSONALIZED MEDICINE COALITION | 2 | $85K | Q4 2024 | Q3 2024 | yes | |
| HEALTHCARE LEADERSHIP COUNCIL | 1 | $110K | Q3 2024 | Q3 2024 | yes | |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 1 | $310K | Q4 2024 | Q4 2024 | yes | |
| PFIZER, INC. | AVOQ, LLC | 1 | $0 | Q1 2024 | Q1 2024 | yes |